Neuland Laboratories Ltd
NEULANDLABNeuland Laboratories Ltd's earnings have outrun its stock. EPS grew +39.9% in a year against a +29.2% price move.
The sharpest disagreement: the engine is strong, but at the 87th percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (10 weeks in) while the P/E sits at the 87th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +660.7% year on year, and 100% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Neuland Laboratories Ltd trades at ₹18,434, in a confirmed uptrend and 10 weeks into that stage. That is +19.0% against its own 200-day average. It sits at 86% of a 52-week range of ₹11,995 to ₹19,506. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 21 straight weeks.
Today the stock is in a confirmed uptrend — week 10 of stage 2, confirmed. At ₹18,434 it trades +19.0% versus its 200-day average and sits at 86% of its 52-week range (₹11,995–₹19,506).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +2,885% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 21 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 87th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Neuland Laboratories Ltd trades at 65.9× P/E, at the pricey end of its own range (87th percentile). Its long-run median P/E is 34.5×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 65.9× is at the pricey end of its own range (87th percentile), against a long-run median of 34.5× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +39.9% against a +29.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +53.0%/yr price move, ~+38.5%/yr came from earnings growth and ~+14.5 pp from the multiple (expanding); over 10y, of the +34.0%/yr price move, ~+24.8%/yr came from earnings growth and ~+9.2 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Neuland Laboratories Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −40.2% at the trough to +39.8%, a 2-quarter improving streak, ROCE lifting at 26.0%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +37.0% | +19.3% | +16.6% | +14.8% |
| Profit | +40.0% | +30.4% | +35.1% | +29.7% |
| EPS | +39.9% | +30.6% | +35.2% | +24.9% |
| Share price | +29.2% | +83.8% | +53.0% | +34.0% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
75.0/100 — rank 2 of 24 in Pharma - API & CRAMS · 96% evidence confidence
Neuland Laboratories Ltd scores 75.0 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 2. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 30.3 + 19.5 + 12 + 13.2 = 75. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Neuland Laboratories Ltd reported ₹776 Cr of revenue in the Mar 26 quarter, +136.6% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 14.8% a year. The last full year, FY26, came in at ₹2,023 Cr. The last four reported quarters add to ₹2,023 Cr.
Neuland Laboratories Ltd reported ₹776 Cr of revenue in the Mar 26 quarter, +136.6% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 14.8% a year. The last full year, FY26, came in at ₹2,023 Cr. The last four reported quarters add to ₹2,023 Cr.
FY26 revenue came in at ₹2,023 Cr (+37.0% on the year), capping 10 years at 14.8% compound. The latest quarter (Mar 26) printed ₹776 Cr, +136.6% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +44.8% growth against the decade's 14.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +37.0% over the last 4 quarters against +13.9%/yr over the last 8 — accelerating; TTM profit +39.8% vs +10.3%/yr — accelerating.
→ Revenue grew — did margins hold as it scaled? Next: 40.0% this quarter (+24.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Neuland Laboratories Ltd's operating margin is 40.0% in the Mar 26 quarter, +24.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0% to 30.0%. The current quarter is running above every full year in that window.
Neuland Laboratories Ltd's operating margin is 40.0% in the Mar 26 quarter, +24.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0% to 30.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 40.0%, +24.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0%–30.0%.
Why the margin moved: operating margin went +24.0 pp year on year while gross margin went +4.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins held — did that reach the bottom line? Next: profit +660.7% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Neuland Laboratories Ltd earned ₹213 Cr of net profit in the Mar 26 quarter, +660.7% year on year. Full-year FY26 profit was ₹364 Cr. The 10-year compound rate is 29.7%. That is 27.4% of the quarter's revenue. The same quarter a year earlier earned ₹28.0 Cr.
Neuland Laboratories Ltd earned ₹213 Cr of net profit in the Mar 26 quarter, +660.7% year on year. Full-year FY26 profit was ₹364 Cr. The 10-year compound rate is 29.7%. That is 27.4% of the quarter's revenue. The same quarter a year earlier earned ₹28.0 Cr.
Mar 26 profit was ₹213 Cr, +660.7% year on year. On the full year, FY26 printed ₹364 Cr (+40.0%), and the 10-year compound rate is 29.7%.
Why profit moved: revenue contributed +136.6% and the margin +24.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +177.3% vs revenue +44.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 100% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 100% of Neuland Laboratories Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹347 Cr of operating cash against ₹364 Cr of profit. After ₹477 Cr of capital spending, ₹−130 Cr was left as free cash.
FY26: operating cash of ₹347 Cr against reported profit of ₹364 Cr, leaving free cash of ₹−130 Cr after ₹477 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 100% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 100%: the cash cycle stretched 50 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 3.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹807 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Neuland Laboratories Ltd's cash conversion cycle runs 214 days in FY26, up from 164 days in FY21. Capital spending ran ₹807 Cr over the last 3 years. At FY26 sales of ₹2,023 Cr each day of that cycle holds about ₹5.5 Cr, so roughly ₹1,186 Cr sits inside the business at any moment.
FY26: debtors at 98 days, inventory at 245 days — roughly 8.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 214 days, looser than FY21's 164.
The full loop: cash goes out to suppliers and production on day 0; stock waits 245 days to sell; customers pay about 98 days after that; and suppliers themselves are paid at 129 days — netting out to the 214-day cycle.
In money terms: at FY26 sales of ₹2,023 Cr, each day of the cycle holds about ₹5.5 Cr — so the 214-day loop keeps roughly ₹1,186 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹807 Cr over the last 3 fiscal years against ₹218 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹211 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 26% and the ROIC − WACC spread is +7.0 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Neuland Laboratories Ltd earns a ROCE of 26% in FY26. That is up from a trough of 4% in FY18. Return on invested capital clears the cost of that capital by +7.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 18.0% net margin on 0.69× asset turns.
FY26 ROCE is 26%, recovered from a FY18 trough of 4% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 18.0% net margin × 0.69× asset turns × 1.56× balance-sheet leverage ≈ 19.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 19.0% − 12.0% = a +7.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.16.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Neuland Laboratories Ltd carries total debt of ₹301 Cr against shareholder equity of ₹1,874 Cr as of Mar 26, a debt-to-equity of 0.16 — effectively unlevered. On the annual view that ratio went from 0.29 in FY22 to 0.16 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹301 Cr against shareholder equity of ₹1,874 Cr — a debt-to-equity of 0.16. On the annual view, debt-to-equity went from 0.29 (FY22) to 0.16 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 10.1 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 10.1 points of Neuland Laboratories Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 16.5% of the company. Foreign institutions moved −4.6 points over the same window, to 21.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +10.1 points over 8 quarters to 16.5%; Foreign institutions: −4.6 points over 8 quarters to 21.1%; Promoters: −0.1 points over 8 quarters to 32.6%.
Why the register moved: rotation — foreign institutions −4.6 points against domestic institutions +10.1 points over 8 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Neuland Laboratories Ltd: the Z-score reads 12.34. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 12.34 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 12.34.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Neuland Laboratories Ltd this page | 65.9× | ₹23,794 Cr | Turning around | |||
| Divis Laboratories Ltd | 73.4× | ₹1.9L Cr | Mixed | |||
| Laurus Labs Ltd | 79.1× | ₹86,505 Cr | Mixed | |||
| Anthem Biosciences Ltd | 73.1× | ₹43,360 Cr | No read | |||
| Gland Pharma Ltd | 37.6× | ₹39,257 Cr | Improving | |||
| Acutaas Chemicals Ltd | 75.2× | ₹26,785 Cr | Improving | |||
| Acutaas Chemicals Ltd | 69.1× | ₹26,686 Cr | Mixed | |||
| Sai Life Sciences Ltd | 73.8× | ₹26,174 Cr | No read | |||
| Piramal Pharma Ltd | — | ₹24,133 Cr | No read | |||
| Granules India Ltd | 31.8× | ₹20,655 Cr | Consistent | |||
| OneSource Specialty Pharma Ltd | — | ₹18,961 Cr | No read | |||
| Syngene International Ltd | 44.9× | ₹16,708 Cr | Turning around | |||
| Syngene International Ltd | 44.1× | ₹16,415 Cr | Turning around | |||
| Cohance Lifesciences Ltd | 80.9× | ₹15,957 Cr | Deteriorating | |||
| Jubilant Pharmova Ltd | 35.2× | ₹15,378 Cr | No read | |||
| Concord Biotech Ltd | 54.8× | ₹13,061 Cr | Deteriorating | |||
| Shilpa Medicare Ltd | 50.8× | ₹11,856 Cr | No read | |||
| Blue Jet Healthcare Ltd | 43.3× | ₹10,730 Cr | Deteriorating | |||
| Supriya Lifescience Ltd | 32.3× | ₹6,765 Cr | Consistent | |||
| IOL Chemicals & Pharmaceuticals Ltd | 30.0× | ₹4,380 Cr | Improving | |||
| SMS Pharmaceuticals Ltd | 35.0× | ₹3,569 Cr | Mixed | |||
| Morepen Laboratories Ltd | 39.6× | ₹2,948 Cr | Mixed | |||
| Dishman Carbogen Amcis Ltd | 29.0× | ₹2,878 Cr | No read | |||
| Hikal Ltd | 73.8× | ₹2,681 Cr | Deteriorating | |||
| Solara Active Pharma Sciences Ltd | 551.0× | ₹2,351 Cr | No read | |||
| Windlas Biotech Ltd | 26.6× | ₹1,770 Cr | Mixed |
Frequently asked questions
What is Neuland Laboratories Ltd's share price today?
Neuland Laboratories Ltd trades at ₹18,434, +29.2% over the past year. The company is valued at ₹23,794 Cr. The stock sits at 86% of its 52-week range of ₹11,995–₹19,506, +19.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 10 weeks in. — as of 24 July 2026.
What were Neuland Laboratories Ltd's latest quarterly results?
Neuland Laboratories Ltd reported revenue of ₹776 Cr and net profit of ₹213 Cr for the Mar 26 quarter. Revenue rose 136.6% and profit rose 660.7% year on year. Earnings per share were ₹165.76. The operating margin was 40.0%, 24.0 pp higher than a year earlier. — as of 24 July 2026.
What is Neuland Laboratories Ltd's revenue?
Neuland Laboratories Ltd reported revenue of ₹776 Cr in the Mar 26 quarter, +136.6% year on year. For the full FY26 fiscal year, revenue was ₹2,023 Cr (+37.0%). Over the last 10 years revenue compounded at 14.8% a year. — as of 24 July 2026.
What is Neuland Laboratories Ltd's profit?
Neuland Laboratories Ltd earned ₹213 Cr of net profit in the Mar 26 quarter, +660.7% year on year. Full-year FY26 profit was ₹364 Cr. The operating margin ran 40.0% in the latest quarter. — as of 24 July 2026.
What is Neuland Laboratories Ltd's market cap?
Neuland Laboratories Ltd's market capitalisation is ₹23,794 Cr at a share price of ₹18,434. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Neuland Laboratories Ltd's P/E ratio?
Neuland Laboratories Ltd trades at a P/E of 65.9×, at the 87th percentile of its own 10-year range, against a long-run median of 34.5×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Neuland Laboratories Ltd pay a dividend?
Yes — Neuland Laboratories Ltd's dividend payout was 12% of profit in FY26, and it recorded a payout in 10 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Neuland Laboratories Ltd overvalued?
On its own history, Neuland Laboratories Ltd looks expensive against its own history: its P/E of 65.9× sits at the 87th percentile of its 10-year range (long-run median 34.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Neuland Laboratories Ltd growing?
Yes — Neuland Laboratories Ltd is growing: latest-quarter revenue +136.6% year on year, profit +660.7%, and the margin +24.0 pp at 40.0%. The 10-year compound rates are 14.8% (revenue) and 29.7% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Neuland Laboratories Ltd performing?
Neuland Laboratories Ltd is in a confirmed uptrend, 10 weeks in. Its latest quarter's revenue rose 136.6% and profit rose 660.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 21 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Neuland Laboratories Ltd in?
Turning around — profit growth swung from −40.2% at the trough to +39.8%, a 2-quarter improving streak, ROCE lifting at 26.0%. The read comes from the last 12 quarters of growth (revenue growth +37.0% latest, profit growth +39.8% latest, eps growth +39.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Neuland Laboratories Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 10 of stage 2), trading +19.0% versus its 200-day average and at 86% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Neuland Laboratories Ltd beating the market?
On recent form, yes — Neuland Laboratories Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 21 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +2,885% against the NIFTY 500's +274% — ahead of the index over the full window. — as of 24 July 2026.
Will Neuland Laboratories Ltd's share price go up?
This page publishes no price forecast for Neuland Laboratories Ltd. What it measures instead: the share price is ₹18,434, the price is in a confirmed uptrend 10 weeks in. Its P/E of 65.9× sits at the 87th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Neuland Laboratories Ltd?
Promoters hold 32.6% of Neuland Laboratories Ltd, foreign institutions 21.1%, domestic institutions 16.5% and the public 29.8% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 10.1 points over 8 quarters. — as of 24 July 2026.
Does Neuland Laboratories Ltd have too much debt?
No — Neuland Laboratories Ltd's debt-to-equity is 0.16, and operating profit covers the interest bill 24×. FY26 borrowings were ₹301 Cr against equity of ₹1,875 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Neuland Laboratories Ltd's capex?
Neuland Laboratories Ltd spent ₹807 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹477 Cr, with ₹211 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Neuland Laboratories Ltd's cash flow?
Neuland Laboratories Ltd generated ₹347 Cr of operating cash flow in FY26 and ₹−130 Cr of free cash flow after ₹477 Cr of capital spending. Reported profit that year was ₹364 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Neuland Laboratories Ltd's profit real cash?
Yes — over the last 3 fiscal years, 100% of Neuland Laboratories Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹347 Cr against reported profit of ₹364 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Neuland Laboratories Ltd?
On the balance sheet, the Z-score reads 12.34 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Neuland Laboratories Ltd in its business cycle?
Neuland Laboratories Ltd's FY26 operating margin was 29.0%, against a 13-year band of 9.0%–30.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 40.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Neuland Laboratories Ltd story?
The sharpest disagreement: the engine is strong, but at the 87th percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Neuland Laboratories Ltd a stock worth studying right now?
This is not investment advice. The machine read: Neuland Laboratories Ltd's earnings have outrun its stock. EPS grew +39.9% in a year against a +29.2% price move. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.